Who
Stephen George Dilly
Director
Company insider
Files Form 4 as: Director and Officer, Codexis; CEO and President, Sierra Oncology; Director, Sangamo Therapeutics; President and CEO, Aimmune Therapeutics; Director, Avigen Inc \de.
In numbers
- Trades disclosed
- 118
- Buys
- 2
- Sells
- 22
- Bought
- $190K
- Sold
- $21.8M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 5 Feb 2007
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —66,350 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —66,350 at $0.00 | filing |
| 11 Nov 2025filed 12 Nov 2025 | CDXS CodexisChemicals | SEC FORM 4 Code A | $93K50,000 at $1.85 | filing |
| 5 Feb 2025filed 7 Feb 2025 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —532,500 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | CDXS CodexisChemicals | SEC FORM 4 Code A | —88,750 at $0.00 | filing |
| 1 Jan 2024filed 2 Jan 2024 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —860,500 at $0.00 | filing |
| 1 Jan 2024filed 2 Jan 2024 | CDXS CodexisChemicals | SEC FORM 4 Code A | —143,425 at $0.00 | filing |
| 8 Sep 2023filed 12 Sep 2023 | CDXS CodexisChemicals | SEC FORM 4 Bought | $101K58,479 at $1.73 | filing |
| 8 Mar 2023filed 9 Mar 2023 | CDXS CodexisChemicals | SEC FORM 4 Sold | $123K26,987 at $4.56 | filing |
| 7 Mar 2023filed 9 Mar 2023 | CDXS CodexisChemicals | SEC FORM 4 Sold | $129K28,088 at $4.60 | filing |
| 21 Feb 2023filed 21 Feb 2023 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —337,500 at $0.00 | filing |
| 21 Feb 2023filed 21 Feb 2023 | CDXS CodexisChemicals | SEC FORM 4 Code A | —112,500 at $0.00 | filing |
| 8 Feb 2023filed 9 Mar 2023 | CDXS CodexisChemicals | SEC FORM 4 Code A | —289,000 at $0.00 | filing |
| 1 Aug 2022filed 3 Aug 2022 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 1 Jul 2022filed 1 Jul 2022 | Sierra Oncologyoption or derivative | SEC FORM 4 Code D | —520,000 at $0.00 | filing |
| 1 Jul 2022filed 1 Jul 2022 | Sierra Oncologyoption or derivative | SEC FORM 4 Code D | —260,000 at $0.00 | filing |
| 1 Jul 2022filed 1 Jul 2022 | Sierra Oncologyoption or derivative | SEC FORM 4 Code D | —92,000 at $0.00 | filing |
| 1 Jul 2022filed 1 Jul 2022 | Sierra Oncologyoption or derivative | SEC FORM 4 Code D | —165,000 at $0.00 | filing |
| 1 Jul 2022filed 1 Jul 2022 | Sierra Oncology | SEC FORM 4 Code D | $275K5,000 at $55.00 | filing |
| 17 Jun 2022filed 17 Jun 2022 | Sierra Oncologyoption or derivative | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
News
Codexis (NASDAQ:CDXS) and Revvity (NYSE:RVTY) Head-To-Head ComparisonCDXS · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Stephen George Dilly; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.